Nippon Soda Co., Ltd. - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Nippon Soda Co., Ltd.

High viscosity grade Nisso HPC-H (hydroxypropyl cellulose) offers advantages as a controlled release polymer when compared to HPMC in a sustained release matrix tablet application. In a direct compression application, HPC-H (fine powder type) sustains drug release more effectively than HPMC in the case of equivalent viscosity of the two polymers. Further, HPC-H has equivalent control release performance to HPMC 100000 while HPC-H has much lower viscosity, and this result is found when the tablet is prepared using either direct compression or wet granulation method.

Fig. 1: Effect of CR material (HPC vs HPMC, direct compression method)

Effect of CR Material (DC Method) is as shown in Fig 1. In the case of DC method, HPC-H-FP sustained drug release more than HPMC 4000, and showed equivalent release control performance to HPMC 100000 while its viscosity was much lower.

Fig 2: Effect of CR Material (HPC vs. HPMC, wet granulation method)

Effect of CR Polymer (WG Method) is as shown in Fig. 2. In the case of WG method, much difference was not seen in comparison of drug release from tablet prepared by HPC-H and HPC-H-FP. Also, Both HPC-H and HPC-H-FP showed equivalent release control performance to HPMC 100000. Drug release from tablet prepared by HPMC 4000 was much faster than the others.

Click here to download a white paper with complete data.

Contact info:
Catherine Cote
Nisso America Inc.
88 Pine Street, 14th Fl
New York, NY 10005

Nisso Chemical Europe GmbH
Naoki Kuwada


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here